Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Exp Neurol ; 330: 113357, 2020 08.
Article in English | MEDLINE | ID: mdl-32437708

ABSTRACT

BACKGROUND: Cognitive dysfunction is one of the most disabling non-motor symptoms of Parkinson's disease (PD), though its pathological correlates still remain elusive. Hippocampal Lewy pathology has recently been correlated by compelling evidence from post-mortem and imaging studies. Animal models recapitulating cognitive impairment in PD are essential to better understand the underlying pathophysiology. To investigate the hippocampal involvement in cognitive dysfunction of PD, we generated an experimental model by inducing midbrain and hippocampal α-synuclein pathology simultaneously. METHODS: Rats were injected either with human α-synuclein or green fluorescent protein (GFP) expressing adeno-associated viral vectors (AAV), or saline bilaterally into substantia nigra (SN) and dentate gyrus (DG). A group of untreated animals were used as naïve controls. Cognitive and behavioral changes were evaluated with tests probing for spatial learning, short-term memory, anxiety and hedonistic behavior. Immunohistochemical staining, immunoblotting and stereological analysis were performed for pathological characterization. RESULTS: Bilateral α-synuclein overexpression in SN and DG led to mild but significant motor impairment as well as dysfunctions in short-term memory and spatial learning. There was no hedonistic deficit, whereas a hypo-anxious state was induced. While stereological analysis revealed no significant neuronal loss in any sectors of cornu ammonis, there was considerable decrease (43%) in TH+-neurons in SN pars compacta supporting the well-known vulnerability of nigral dopaminergic neurons to α-synuclein mediated neurodegeneration. On the other hand, synaptophysin levels decreased in similar amounts both in striatum and hippocampus, suggesting comparable synaptic loss in target areas. Interestingly, phosphorylated-S129-α-synuclein staining revealed significant expression in CA2 characterized by more mature and dense cellular accumulations compared to CA1-CA3 sub-regions displaying more diffuse grain-like aggregates, suggesting preferential susceptibility of CA2 to produce α-synuclein induced pathology. CONCLUSION: Bilateral α-synuclein overexpression in DG and SN reproduced partial motor and hippocampus related cognitive deficits. Using this model, we showed a predisposition of CA2 for pathological α-synuclein accumulation, which may provide further insights for future experimental and clinical studies.


Subject(s)
CA2 Region, Hippocampal/pathology , Cognitive Dysfunction , Disease Models, Animal , Parkinson Disease/pathology , alpha-Synuclein/toxicity , Animals , Dentate Gyrus/pathology , Female , Humans , Rats , Rats, Sprague-Dawley , Substantia Nigra/pathology
2.
Arch Pharm (Weinheim) ; 350(7)2017 Jul.
Article in English | MEDLINE | ID: mdl-28594090

ABSTRACT

Previously, we demonstrated that certain heterocyclic compounds derived from 3-substituted-1,2,4-triazole-5-thiones had promising analgesic/anti-inflammatory activities together with low ulcerogenic properties. Therefore, we sought to design and synthesize new derivatives of triazol-5-thiones-fused heterocycles. In the present study, a series of novel bis-Mannich bases, namely 2,6-disubstituted-6,7-dihydro-5H-1,2,4-triazolo[3,2-b]-1,3,5-thiadiazines (1a-d, 2a-c, and 3a-d), were synthesized and characterized to assess their possible anti-inflammatory/analgesic properties. Additionally, their ability to induce gastric toxicity was also evaluated. Several of the condensed compounds produced a degree of analgesic activity comparable to reference drugs in both the hot plate and tail-flick tests. A strong anti-inflammatory effect was observed for the derivatives carrying a benzyl group at the second position (2a-c). The majority of the prepared compounds caused comparatively less gastrointestinal (GI) side effects than the reference drugs naproxen and indomethacin did. These results showed that 1,2,4-triazolo[3,2-b]-1,3,5-thiadiazine derivatives might afford a safer alternative to currently available analgesic/anti-inflammatory agents for the treatment and management of inflammatory disease and pain.


Subject(s)
Analgesics/pharmacology , Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Drug Design , Edema/drug therapy , Pain/drug therapy , Stomach Ulcer/drug therapy , Thiadiazines/pharmacology , Triazoles/pharmacology , Analgesics/chemical synthesis , Analgesics/chemistry , Animals , Anti-Inflammatory Agents, Non-Steroidal/chemical synthesis , Anti-Inflammatory Agents, Non-Steroidal/chemistry , Behavior, Animal/drug effects , Carrageenan , Disease Models, Animal , Edema/chemically induced , Hot Temperature , Mice , Molecular Structure , Stomach Ulcer/chemically induced , Thiadiazines/chemical synthesis , Thiadiazines/chemistry , Triazoles/chemical synthesis , Triazoles/chemistry
3.
Exp Neurol ; 212(2): 522-31, 2008 Aug.
Article in English | MEDLINE | ID: mdl-18571649

ABSTRACT

The D2/D3 dopamine receptor agonist pramipexole, protects against toxin-induced dopaminergic neuronal destruction but its mechanism of action is unknown. Inflammation following glial cell activation contributes to cell death in Parkinson's disease and we now report on the effects of acute or chronic administration of pramipexole on lipopolysaccharide (LPS) induced inflammation and nigral dopaminergic cell death in the rat. At 48 h and 30 days following supranigral administration of LPS, approximately 70% of tyrosine hydroxylase (TH) immunoreactive (-ir) cells in substantia nigra had degenerated with a corresponding loss of TH-ir terminals in the striatum. In rats acutely treated with pramipexole (2x1 mg/kg; s.c.) 48 h following LPS application, there was no difference in the number of TH-ir cells or terminals compared to LPS-treated rats receiving vehicle. However, the continuous subcutaneous infusion of pramipexole for 7 days prior to LPS and 21 days subsequently, produced a marked preservation of both TH-ir cells and terminals. At 48 h or 30 days, LPS induced an up-regulation of ubiquitin-ir within the nigral TH-ir neurones, which was reduced by pramipexole treatment. Thirty days following supranigral LPS administration (9 days after the end of infusion), (+)-amphetamine (5 mg/kg, i.p.) caused robust ipsiversive rotation. In rats treated with LPS but receiving continuous subcutaneous administration of pramipexole, (+)-amphetamine-induced rotation was markedly reduced. LPS-induced increase in the levels of inflammatory markers, were not affected by either acute administration or continuous infusion of pramipexole. Continuous infusion of pramipexole protected dopaminergic neurones against inflammation induced degeneration but without modification of the inflammatory response.


Subject(s)
Benzothiazoles/administration & dosage , Dopamine Agonists/administration & dosage , Dopamine/metabolism , Inflammation/pathology , Amphetamine/pharmacology , Animals , Behavior, Animal/drug effects , Cell Count , Cell Death/drug effects , Dopamine Uptake Inhibitors/pharmacology , Drug Interactions , Inflammation/chemically induced , Inflammation/drug therapy , Injections, Subcutaneous/methods , Lipopolysaccharides , Male , Motor Activity/drug effects , Neurons/drug effects , Neurons/metabolism , Pramipexole , Rats , Rats, Wistar , Substantia Nigra/drug effects , Time Factors , Tyrosine 3-Monooxygenase/metabolism
4.
Brain Res Mol Brain Res ; 110(2): 169-76, 2003 Feb 20.
Article in English | MEDLINE | ID: mdl-12591154

ABSTRACT

High levels of neuropeptide Y (NPY) are found in basal ganglia where it is co-localised with somatostatin (SOM) and nicotinamide adenine dinucleotide phosphate-diaphorase (NADPH/d) in a population of striatal GABA containing interneurones. Although alterations occur in the levels of various neuropeptides in basal ganglia in Parkinson's disease (PD), it is not known whether NPY is affected. Using in situ hybridisation immunohistochemistry, we have examined the distribution of NPY mRNA in the caudate nucleus, putamen and nucleus accumbens of normal individuals and patients with PD. NPY mRNA was weakly expressed in the caudate nucleus, putamen and nucleus accumbens in normal individuals with a scattered labelling of neurones. However, there was no regional localisation within any brain area and no obvious differences between brain regions. In PD, the number of NPY mRNA-expressing cells was increased as was the density of the silver grains overlying each positive cell. The increase was more pronounced in the nucleus accumbens and in the ventral part of the caudate nucleus. The increase in NPY mRNA expression observed in patients with PD may reflect the loss of dopaminergic tone on striatal NPY containing interneurones, although a role for chronic L-DOPA therapy cannot be ruled out.


Subject(s)
Corpus Striatum/metabolism , Interneurons/metabolism , Neuropeptide Y/genetics , Parkinson Disease/metabolism , Aged , Caudate Nucleus/metabolism , Caudate Nucleus/pathology , Caudate Nucleus/physiopathology , Corpus Striatum/pathology , Corpus Striatum/physiopathology , Female , Gene Expression Regulation/genetics , Humans , Male , Middle Aged , Nucleus Accumbens/metabolism , Nucleus Accumbens/pathology , Nucleus Accumbens/physiopathology , Parkinson Disease/pathology , Parkinson Disease/physiopathology , Putamen/metabolism , Putamen/pathology , Putamen/physiopathology , RNA, Messenger/metabolism
5.
Mov Disord ; 17(5): 887-901, 2002 Sep.
Article in English | MEDLINE | ID: mdl-12360537

ABSTRACT

Piribedil ([1-(3,4-methylenedioxybenzyl)-4-(2-pyrimidinyl)piperazine]; S 4200) is a dopamine agonist with equal affinity for D(2)/D(3) dopamine receptors effective in treating Parkinson's disease as monotherapy or as an adjunct to levodopa (L-dopa). However, its ability to prime basal ganglia for the appearance of dyskinesia is unknown. We now report on the ability of repeated administration of piribedil to induce dyskinesia in drug naïve 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) -lesioned common marmosets compared with L-dopa and its actions on the direct and indirect striatal outflow pathways. Administration of piribedil (4.0-5.0 mg/kg orally) or L-dopa (12.5 mg/kg orally plus carbidopa 12.5 mg/kg orally twice daily) produced equivalent increases in locomotor activity and reversal of motor deficits over a 28-day study period. Administration of L-dopa resulted in the progressive development of marked dyskinesia over the period of study. In contrast, administration of piribedil produced a significantly lower degree and intensity of dyskinesia. Surprisingly, piribedil caused an increase in vigilance and alertness compared to L-dopa, which may relate to the recently discovered alpha(2)-noradrenergic antagonist properties of piribedil. The behavioural differences between piribedil and L-dopa are reflected in the biochemical changes associated with the direct striatal output pathway. Administration of L-dopa or piribedil did not reverse the MPTP-induced up-regulation of preproenkephalin A mRNA in rostral or caudal areas of the putamen or caudate nucleus. In contrast, administration of either piribedil or L-dopa reversed the downregulation of preprotachykinin mRNA induced by MPTP in rostral and caudal striatum. L-dopa, but not Piribedil, reversed the decrease in preproenkephalin B mRNA produced by MPTP treatment.


Subject(s)
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine/adverse effects , Antiparkinson Agents/therapeutic use , Dyskinesia, Drug-Induced/etiology , Dyskinesias/diagnosis , Dyskinesias/drug therapy , Levodopa/adverse effects , Piribedil/therapeutic use , Animals , Antiparkinson Agents/administration & dosage , Antiparkinson Agents/adverse effects , Arousal/drug effects , Callithrix , Caudate Nucleus/metabolism , Corpus Striatum/metabolism , Culture Techniques , Drug Administration Schedule , Dyskinesias/metabolism , Female , In Situ Hybridization , Locomotion/drug effects , Male , Piribedil/administration & dosage , Piribedil/adverse effects , RNA, Messenger/metabolism , Severity of Illness Index , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...